v3.26.1
Segment information - Schedule of Financial Data for the Company's Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]        
Revenue $ 0 $ 500 $ 0 $ 500
Research and development expenses (1,808) (5,373) (6,555) (9,303)
General and administrative expenses (5,222) (5,494) (9,241) (12,766)
Net loss before income tax (7,005) (14,616) (13,724) (27,503)
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Revenue 0 500 0 500
Cost of revenue 0 (132) 0 (132)
Other (50) (66) (108) (181)
General and administrative expenses (5,222) (5,494) (9,241) (12,766)
Other segment items 25 (4,117) 2,072 (5,802)
Net loss before income tax (7,005) (14,616) (13,724) (27,503)
Operating Segments [Member] | Setrusumab (BPS-804/UX143) [Member]        
Segment Reporting Information [Line Items]        
Research and development expenses (1,112) (3,687) (5,164) (5,930)
Operating Segments [Member] | Alvelestat (MPH-966) [Member]        
Segment Reporting Information [Line Items]        
Research and development expenses (426) (1,396) (869) (2,761)
Operating Segments [Member] | Etigilimab (MPH-313) [Member]        
Segment Reporting Information [Line Items]        
Research and development expenses $ (220) $ (224) $ (414) $ (431)